We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).
- Authors
Berra, Cesare C.; Rossi, Maria Chiara; Mirani, Marco; Ceccarelli, Daniela Ceccarelli; Romano, Cristina; Sassi, Lorenza; Peretti, Elena; Favacchio, Giuseppe; Pastore, Ida; Folini, Laura; Graziano, Giusi; Lunati, Maria Elena; Solerte, Sebastiano Bruno; Fiorina, Paolo
- Abstract
Introduction: Aim of the present study was to evaluate the real-world impact of once-weekly (OW) subcutaneous semaglutide on different end-points indicative of metabolic control, cardiovascular risk factors, and beta-cell function in type 2 diabetes (T2D). Methods: This was a retrospective, observational study conducted in 5 diabetes clinics in Italy. Changes in HbA1c, fasting blood glucose (FBG), body weight, blood pressure, lipid profile, renal function, and beta-cell function (HOMA-B) during 12 months were evaluated. Results: Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years). After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg. Systolic blood pressure, total and LDLcholesterol significantly improved. Benefits were sustained at 12 months. Renal safety was documented. HOMA-B increased from 40.2% to 57.8% after 6 months (p<0.0001). Discussion: The study highlighted benefits of semaglutide on metabolic control, multiple CV risk factors, and renal safety in the real-world. Semaglutide seems to be an advisable option for preservation of b-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D.
- Subjects
ITALY; TYPE 2 diabetes; SEMAGLUTIDE; SYSTOLIC blood pressure; CARDIOVASCULAR diseases risk factors; COHORT analysis
- Publication
Frontiers in Endocrinology, 2023, Vol 13, p1
- ISSN
1664-2392
- Publication type
Academic Journal
- DOI
10.3389/fendo.2022.1099451